marked.bio

Company

Pierre Fabre Medicament

5 active trials that select patients by a biomarker on marked.bio, across 4 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

encorafenib 2binimetinib 2

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

5 of 9 trials shown

  1. Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

    Active, not recruiting Phase 3 Pierre Fabre Medicament Started 2022Primary completion 2027-03 NCT05270044

    encorafenib FDA EUbinimetinib FDA EU

    Available tumour sample for central determination of the BRAF V600E/K mutation.

    BRAF V600EStatus may be outdated, last updated 2023-11-22Melanoma

  2. Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

    Recruiting Phase 1/2 Pierre Fabre Medicament Started 2024Primary completion 2027-11 NCT06567015

    STX-241

    Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th editi…

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC)

  3. FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

    Recruiting Phase 1/2 Pierre Fabre Medicament Started 2024Primary completion 2030-10 NCT06669117

    VERT-002

    METex14 mutation

    MET exon 14 skippingSolid Tumor, MET Alteration

  4. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    Recruiting Phase 1/2 Pierre Fabre Medicament Started 2023Primary completion 2029-12 NCT06043817

    STX-721/PFL-721 (Escalated)STX-721/PFL-721 (3 dose levels)STX-721/PFL-721 (RP2D)

    Part 1: Tumor tissue EGFR or HER2 exon 20 insertion mutations confirmed by qualified local laboratories.

    HER2 (ERBB2) activating mutationNon-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

  5. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Pierre Fabre Medicament Started 2022Primary completion 2024-05 NCT05195632

    encorafenib FDA EUbinimetinib FDA EU

    Presence of B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation in tumor tissue previously determined by a local assay at any time prior to scre…

    BRAF V600ENon-Small Cell Lung Cancer